Regentis Biomaterials Ltd. RGNT
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -79.67%
- 1 year
- -81.73%
- Open
- 1.42
- Prev close
- 1.36
- Mkt cap
- 9.62M
- Vol
- 24.87K
- Avg vol
- 51.58K
- EPS
- -2.46
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.31
- High
- 1.42
5D chart
Signals (47)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 10:15 AM | 2 days ago |
| MACD: Buy Signal | Oct 30, 9:50 AM | 2 days ago |
| RSI: Oversold | Oct 29, 3:55 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:15 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:10 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:10 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 1:10 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 12:35 PM | 3 days ago |
| RSI: Overbought | Oct 29, 12:35 PM | 3 days ago |
| MACD: Sell Signal | Oct 29, 12:25 PM | 3 days ago |
| RSI: Overbought | Oct 29, 11:45 AM | 3 days ago |
| RSI: Overbought | Oct 29, 11:05 AM | 3 days ago |
| RSI: Overbought | Oct 29, 10:25 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 10:10 AM | 3 days ago |
| SMA: Bearish | Oct 29, 9:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:35 AM | 3 days ago |
| RSI: Oversold | Oct 28, 3:55 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 1:00 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 12:55 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 12:05 PM | 4 days ago |
| RSI: Overbought | Oct 28, 11:15 AM | 4 days ago |
| SMA: Bullish | Oct 27, 3:55 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:55 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:45 PM | 5 days ago |
| RSI: Oversold | Oct 27, 2:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:45 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:40 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 12:05 PM | 5 days ago |
| RSI: Oversold | Oct 27, 10:50 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:45 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 10:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:30 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:30 AM | 5 days ago |
| RSI: Overbought | Oct 27, 9:30 AM | 5 days ago |
| RSI: Oversold | Oct 26, 3:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:20 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 3:20 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 2:55 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:35 PM | 6 days ago |
| RSI: Overbought | Oct 26, 1:10 PM | 6 days ago |
News
3 days ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Glaukos (NYSE:GKOS) shares rose 30.8% to $237.26 during Thursday's regular session. The company's market cap stands at $10.7 billion. The company's, Q3 earnings came out yesterday. Teladoc…
-
6 days ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers SciSparc (NASDAQ:SPRC) shares moved upwards by 39.4% to $1.52 during Monday's pre-market session. Xencor (NASDAQ:XNCR) stock moved upwards by 29.46% to $32.6. The company's market cap stands…
2 weeks ago accessnewswire.com
Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC(R) at 8th ICRS Summit in Portugal
Engagement with leading orthopedic surgeons and cartilage repair specialists highlights growing awareness of GelrinC's off-the-shelf regenerative technology GelrinC is CE Mark approved in Europe,…
3 weeks ago accessnewswire.com
Regentis Biomaterials to Present at the 2026 ThinkEquity Conference on October 15 in New York City
HERZLIYA, IL / ACCESS Newswire / October 9, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair…
1 month ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Greenland Mines (NASDAQ:GRML) stock rose 232.6% to $9.48 during Monday's regular session. The company's market cap stands at $9.0 million. GRAIL (NASDAQ:GRAL) shares moved upwards by 31.47%…
1 month ago globenewswire.com
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd.
AUSTIN, Texas, Sept. 18, 2026 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce…
-
1 month ago benzinga.com
Regentis Biomaterials H1 EPS $(0.44) Up From $(1.17) YoY
Regentis Biomaterials (AMEX:RGNT) reported quarterly losses of $(0.44) per share. This is a 62.39 percent increase over losses of $(1.17) per share from the same period last year.
1 month ago accessnewswire.com
Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
Advances GelrinC® U.S. pivotal trial with 43 patients treated; Completion of enrollment expected by approximately year end 2026 Expands European commercialization readiness, including surgeon…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 49.1% to $4.1 during Tuesday's after-market session. The market value of their outstanding shares is at $1.5 million. CalciMedica (NASDAQ:CALC)…
-
3 months ago benzinga.com
Regentis Gets Japan Patent Office Notice of Allowance For Organic Solvent‑Free Protein‑Polymer Conjugate Compositions, Covering GelrinC Manufacturing Process And Ready‑to‑Use Liquid Formulation for Articular Cartilage Repair
Patent expands intellectual property protection in one of the world's largest cartilage repair marketsGelrinC is a cell-free hydrogel delivered in a single ~10-minute procedure eliminating the need…
3 months ago accessnewswire.com
Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology
Patent expands intellectual property protection in one of the world's largest cartilage repair markets GelrinC is a cell-free hydrogel delivered in a single ~10-minute procedure eliminating the need…
-
3 months ago benzinga.com
Regentis Biomaterials Receives European Regulatory Approval For New GelrinC Manufacturing Process
The approval comes as Regentis prepares for the commercial launch of GelrinC® in Europe, enabling the Company to manufacture commercial product using a process that increases production yield by…
3 months ago accessnewswire.com
Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch
European Notified Body approves next-generation manufacturing process that increases production 5-fold, lowers manufacturing costs, improves safety and enables scalable commercial production…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers NextCure (NASDAQ:NXTC) stock increased by 201.4% to $6.57 during Tuesday's regular session. The market value of their outstanding shares is at $7.8 million. Shuttle Pharmaceuticals…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Can Fite Biopharma (AMEX:CANF) shares rose 43.8% to $4.27 during Wednesday's regular session. The company's market cap stands at $6.3 million. Regencell Bioscience (NASDAQ:RGC) stock moved…
4 months ago accessnewswire.com
Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement
HERZLIYA, IL / ACCESS Newswire / June 17, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE American:RGNT), a regenerative medicine company focused on innovative tissue repair…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
4 months ago benzinga.com
Why Is Regentis Biomaterials Stock Rising On Wednesday?
Regentis Biomaterials Ltd. (RGNT) stock rises after withdrawing its Form F-1 registration statement and accelerating European commercialization for GelrinC.
4 months ago benzinga.com
Why La-Z-Boy Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Shares of La-Z-Boy Inc (NYSE: LZB) rose 19.6% in pre-market trading after reporting better-than-expected results and announcing a $300 million share buyback.
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
4 months ago benzinga.com
Why High Tide Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
HITI rose sharply in pre-market trading on strong Q2 results and continued to rise after market open. Other gainers include SLBT, TDIC, IMCC, IVDA, NXTS, CRVO, PAVS, ALBT, and PURR. Losers include…
4 months ago benzinga.com
Regentis Biomaterials Slips 9% After Soaring 506% On Monday — Here's Why RGNT Stock Is Trending
Regentis stock surged 506% Monday after withdrawing its planned public offering, before slipping in after-hours trading.
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
4 months ago benzinga.com
Crude Oil Tumbles Over 5%; Empire State Manufacturing Index Falls In June
US stocks gain on peace agreement with Iran, Nasdaq up 2%, Dow up 1.1%, S&P 500 up 1.54%. Tech shares jump 2.8%, energy stocks fall 3.5%. Empire State manufacturing index drops to 5.7. Industrial…
-
4 months ago benzinga.com
Regentis Biomaterials Withdraws F-1 Registration Statement And Cancels Planned Public Offering
https://www.sec.gov/Archives/edgar/data/1912966/000121390026068601/ea0294796-6k_regentis.htm
4 months ago benzinga.com
Dow Jumps Over 600 Points Following US-Iran Peace Deal
US stocks rise on peace agreement with Iran, Dow up 600 points. Tech sector jumps, energy stocks down. Trump announces deal, oil futures decline.
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
4 months ago benzinga.com
Why Nuvalent Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
GSK to acquire Nuvalent for $10.6 billion, shares rise 38.2%. Other gainers include CCTG, CHAI, RGNT, MTEN, NCRA, ZTG, EPSM, DBI, APLD. Losers include BYAH, NOTV.
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
4 months ago accessnewswire.com
Regentis to Commence European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations Accelerate
GelrinC®, positioned as the first off-the-shelf cell-free hydrogel implant for knee cartilage repair, is approved for sale in the European Union Regentis is growing its network of European Centers of…
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
6 months ago benzinga.com
Why Sterling Infrastructure Shares Are Trading Higher By Over 22%; Here Are 20 Stocks Moving Premarket
Shares of Sterling Infrastructure Inc (NASDAQ: STRL) jumped 22.5% in pre-market trading after reporting better-than-expected Q1 results and raising its FY26 guidance. Other gainers include BLZE,…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
12 Health Care Stocks Moving In Monday's Pre-Market Session
6 months ago accessnewswire.com
Regentis Implements Strategy for Commercial Deployment of GelrinC(R) in Europe Through Collaboration with Humanitas Hospital and Leading Cartilage Repair Expert Prof. Elizaveta Kon
Collaboration with leading European orthopedic center in Italy supports GelrinC® clinical adoption Renowned cartilage regeneration expert Prof. Elizaveta Kon to help lead Regentis Centers of…
7 months ago accessnewswire.com
Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400%
Breakthrough manufacturing process comes in preparation for upcoming commercial launch in Europe planned for later this year Proprietary process is already patented in several countries and is…
8 months ago accessnewswire.com
Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update
$7.4 million in cash expected to provide runway to complete site expansion process and patient enrollment as part of pivotal Phase III FDA trial for GelrinC Already approved in Europe, GelrinC is…
8 months ago accessnewswire.com
Regentis Biomaterials Appoints Dr. Galit Reske as Chief Medical Officer: Brings Strong Track Record of Success in Cartilage Repair
Dr. Reske has proven leadership in clinical development and regulatory affairs following key role in FDA approval of cartilage repair product Agili-C leading to CartiHeal's $330 million acquisition…
9 months ago accessnewswire.com
Regentis Biomaterials Appoints Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC Progresses Towards Commercial Launch in Europe and Advances in U.S. Phase III FDA Trial
GelrinC, the only restorative product for knee cartilage repair, has CE Mark approval in Europe and is currently at the midpoint of a pivotal FDA Phase III trial in the U.S. Ori Gon brings…
9 months ago accessnewswire.com
Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S.
New sites expected to further accelerate patient enrollment, which surpassed 50% in Phase III study, as well as support future clinical programs GelrinC is set to transform cartilage repair market…
9 months ago accessnewswire.com
Regentis' GelrinC Demonstrates Breakthrough in Regenerating Native-Like Cartilage Structure in Knee Repair on MRI Results Confirmed Using a Validated, Regulator-Accepted Method
2 years after treatment, GelrinC-treated patients demonstrated layered cartilage architecture similar to native hyaline cartilage - widely regarded as the gold standard for durable joint function…
9 months ago accessnewswire.com
Regentis' GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation
Marks a world-first as Regentis uses MOCART, a quantitative standard to measure regeneration of cartilage in a clinical trial, as a predefined endpoint New peer-reviewed data published in the…
10 months ago accessnewswire.com
Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC
Patent protects ready to use liquid formulation of GerlinC which improves efficiency and focus for surgeons, resulting in a 10-minute procedure Robust IP portfolio includes 35 issued patents to date…
11 months ago seekingalpha.com
U.S. IPO Weekly Recap: December Kicks Off With 3 Notable Launches In A Week With 7 SPACs
The US IPO market entered the final stretch of the year with a few small listings, a wave of SPACs, and three notable deal launches on the calendar for the week ahead. With markets recovering from a…
11 months ago globenewswire.com
Regentis Biomaterials Ltd. Announces Closing of Initial Public Offering
Herzliya, Israel, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Regentis Biomaterials Ltd. (NYSE American: RGNT) (“Regentis”, or the “Company”), a regenerative medicine company dedicated to developing innovative…